Medicinal Synthetic Aluminum-Magnesium Silicate
\(\{\text{Al}_4(\text{SiO}_4)_3 + 3\text{Mg}_2\text{SiO}_4 \rightarrow 2\text{Al}_2\text{Mg}_3(\text{SiO}_4)_3}\}\) —A Highly Active Anti-Retroviral Medicine

Maduike C. O. Ezeibe, Ijeoma J. Ogbonna

Department of Veterinary Medicine, Michael Okpara University of Agriculture, Umudike, Nigeria
Email: maduikeezieibe@yahoo.com

Received 8 November 2015; accepted 19 April 2016; published 22 April 2016

Copyright © 2016 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract
Medicinal synthetic Aluminum-magnesium silicate (MSAMS), which has inhibited Human immune deficiency virus (HIV), \textit{in vitro}, was used for trial-treatment of HIV/AIDS patients. Their plasma were tested for viral loads (VL): before and repeatedly during the treatment. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immunace extra protection®. After 4 weeks, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When VL decreased bellow 50/ml, the treatment continued, 4 weeks before stopping. Mean-VL of four patients increased (\(P = 0.006\)) from 498.50 ± 33.37 to 1,072.50 ± 184.55, after 3.75±2.06 weeks and decreased (\(P = 0.040\)) to 407.33 ± 297.27 (18.29%) when the treatment-duration increased to 6.67 ± 2.31 weeks. Prolonging the duration to 12.00 ± 2.83 weeks led to 98.68% decrease of mean-VL of four other patients, from 24,250.00 ± 15,939.34 to 321.00 ± 229.38(\(P = 0.045\)). Two HIV positive persons treated for 4 weeks after their VL reduced bellow 50/ml have remained healthy, 10 and 16 months respectively, without routine antiretroviral medication.

Keywords
MSAMS-Nanoparticles, Unmasking "Hidden Infections", Moping-Out HIV, Access to All Organs/Tissues

1. Introduction
Inhibition of attachment of viruses to cells of their hosts is one of the mechanisms of actions of antiviral medi-
cines [1] and molecules of Aluminum-magnesium silicate (AMS) consist of Nanoparticles [2] [3] which have negative electrical charges on their surfaces and positive charges on their edges while viruses have either net positive electrical charges or net negative charges. HIV has net positive electrical charges [4]. So, AMS can inhibit attachment of HIV to cells of its hosts. The AMS is already in use as a medicine and results of toxicity tests confirm that it is very safe [5]. That means, it can be used as antiretroviral medicine.

The negative and positive electrically charged ends which Nanoparticles of AMS have, give it broad-spectrum antiviral activities, because their surfaces inhibit attachment of positively charged viruses to cells, while their edges inhibit negatively charged viruses. When significant percentage of population of a virus that has infected an animal or a man is inhibited by AMS, immunity completes termination of the infection. Ultra-small size of the particles makes it possible for them to pass physiological barriers, to gain access to viruses in every organ/tissue and in every body-system. By mopping out HIV, AMS may inhibit millions of new particles of the virus, usually released from each infected cell, from establishing their own foci of the infection. Thus, HIV-infections would no longer progress to the acquired immune-deficiency syndrome (AIDS) stage. When AIDS is prevented, immunity clears HIV infections [6].

Nigeria does not have AMS, as a natural resource, but there is abundance of deposits of Aluminum silicate \( \text{Al}_4(\text{SiO}_4)_3 \) and Magnesium silicate \( \text{Mg}_2\text{SiO}_4 \) in the country. These two minerals are also medicines that are already being used for treatments [7]. To get a purer form of AMS \( \text{Al}_2\text{Mg}_3(\text{SiO}_4)_3 \), the two medicinal minerals were reacted [8]. Dextrose monohydrate was formulated with the medicinal synthetic AMS (MSAMS), to carry its molecules, by active transport [9], across mucous membranes of the gastro-intestinal tract, into blood which carries them to all organs/tissues and to all body systems.

The MSAMS has inhibited HIV, in vitro [10] and cured animals infected with viruses of Paramyxoviridae, Birnaviridae and Parvoviridae families [11]-[13]. A histopathologic study revealed that it inhibited activities of Canine parvovirus in organs of infected dogs [12]. The medicine has therefore been on repeated clinical trials, for antiretroviral effects.

2. Materials and Methods

For present study, a formulation [14] of the MSAMS and Ampicillin trihydrate (Antivir A®) and a formulation of the MSAMS alone (Antivir B®) were used to treat eight patients. Each of the patients had to volunteer for the clinical trial by applying through his/her physician. They had their plasma tested for HIV viral load (copies of RNA/ml) before the treatment. The test for viral loads was repeated several times, on each patient, during the treatment. For the first 4 weeks, they were treated, daily, with 50 mg/kg (MSAMS), 7.5 mg/kg (MSAMS-stabilized Ampicillin trihydrate) and Vitabiotics’ immunace extra protection® (1 tablet per day). Thereafter, they were on 50 mg/kg (MSAMS) and the immune stimulant, only. When viral load of a patient reduced below 50/ml the treatment was continued for additional 4 weeks and then stopped.

Means of viral loads of the patients: before the clinical trial, when the viral loads were observed to have increased and when the viral loads started to decrease were compared for statistical differences, by Analysis of variance. Also, mean-duration of the treatment that led to the increase in viral loads and mean of the duration that caused it to start decreasing were calculated. Finally, mean of viral loads of HIV/AIDS patients before the MSAMS-treatment and the mean when the treatment progressed were tested for statistical difference, by the Students’ T-test. Differences in means of viral loads of the different groups were accepted as significant only where the P value was ≤0.050.

3. Results

Viral loads of four of the patients (Table 1) increased (P = 0.006) from 498.50 ± 33.37 to 1,072.50 ± 184.55 (115.29%) after treatment for a mean-duration of 3.75 ± 2.06 weeks and then reduced (P = 0.040) to 407.33 ± 297.27 (18.29%) when the treatment-duration increased to 6.67 ± 2.31 weeks. For four other patients (Table 2) whose mean treatment-duration increased further to 12.00 ± 2.83 weeks the rate of viral load-reduction improved (P = 0.045) to 98.68% (24,250.00 ± 15,939.34 to 321.00 ± 229.38).

4. Discussion

Increases in HIV titre, when HIV-positive plasma were treated with the MSAMS, in vitro [10] and the increases
Table 1. Initial increases and decreases in viral loads of HIV-patients treated with the Medicinal synthetic Aluminum-magnesium silicate.

| Before treatment | Increase (weeks of treatment) | Decrease (weeks of treatment) |
|------------------|------------------------------|------------------------------|
| 500              | 1000 (1)                     | 70 (4)                       |
| 518              | 936 (6)                      | -                            |
| 451              | 1009 (4)                     | 631 (8)                      |
| 525              | 1345 (4)                     | 521 (8)                      |
| Mean             | 498.50 ± 33.37\(^a\)         | 1072.50 ± 184.50\(^b\) (3.75 ± 2.06) |

Table 2. Viral loads of HIV-patients treated with the Medicinal synthetic Aluminum-magnesium silicate.

| Before treatment | After treatment (Duration) |
|------------------|----------------------------|
| 4000             | 1000 (8)                   |
| 1000             | 40 (8)                     |
| 70,000           | 200 (12)                   |
| 22,000           | 44 (20)                    |
| Mean             | 24,250.00 ± 15,939.34      |

in viral loads observed in this *in vivo* study suggest that the MSAMS destroys infected cells to unmask “hidden infections”. The subsequent reductions in titres and in loads of the virus suggest that the AMS-Nanoparticles also mop out extra-cellular HIV.

Increase in rate of reduction of viral load, from 18.28% to 98.68%, when duration of treatment was increased from 6.67 ± 2.31 weeks to 12.00 ± 2.83 weeks suggests that population of HIV mopped out by MSAMS-Nanoparticles increases with prolongation of duration of the medication. Reduction of the viral loads below 50/ml qualifies the MSAMS as a *highly active antiretroviral therapy* (HAART).

That the MSAMS, alone, achieved HAARTs’ effect which is effect of combinations of three or more antiretroviral therapies [15] may be because: AMS-Nanoparticles mop out HIV particles by electrostatic attraction between their negatively charged surfaces and positive charges on the virus; Nanoparticles cross physiological barriers. So, the MSAMS has access to extracellular HIV and HIV-infected cells, both in the blood and in all organs/tissues; Nanoparticles have affinity for abnormal cells [3] while AMS enhances disintegration of drugs [2]. So, the MSAMS may also have destroyed infected cells to unmask “HIV hidden in cells”; The MSAMS may have enhanced efficacy of Ampicillin trihydrate so that secondary infections were more effectively treated [16]-[21]; The MSAMS makes lower doses of drugs (75%) more effective than 100% of the doses [22] [23]. Use of a lower dose (7.5 mg/kg) for treatment may have minimized side effects of Ampicillin trihydrate so that immune systems of the patients functioned optimally. Enhancing immune responses helps to terminate HIV infections [6].

Two of the patients whose viral loads reduced to 40/ml and 44/ml and their treatment was continued for 4 weeks after the test, have remained clinically healthy, without antiretroviral medication for 16 months and for 10 months, respectively. It remains to confirm their HIV status by an antigen test instead of testing for antibodies, since antibodies can remain in blood, long after termination of viral infections.

5. Conclusion

Since the *Medicinal synthetic Aluminum-magnesium silicate*: is a highly active anti-rethroviral therapy; unmasks “hidden infections”; acts both in blood and on organs; mops out more HIV as duration of treatment is prolonged, what is needed to achieve cure for HIV/AIDS may be to continue the treatment long enough after viral loads of patients reduce to <50/ml (by old viral load technique) or to <20/ml (undetectable) by the new technique.
References

[1] Brooks, G.F. (1998) Medical Microbiology. 21st Edition, Mc Graw Hill Education Inc., San Francisco.

[2] Vanderbilt (2012) Report. Technical Information: “VEEGUM—The Versatile Ingredient for Pharmaceutical Formulations. R.T. Vanderbilt Company Bulletin No. 91R, 1984. R.T. Vanderbilt Company, Inc., Norwalk.

[3] Cristina, E., Ivan, P. and Kevin, R. (2007) Nanomaterials and Nanoparticles: Sources and Toxicity. Biointerphases, 2, 17-21.

[4] Yokoyama, M. (2011) Structural Mechanisms of Immune Evasion of HIV 1 gp 120 by Genomic Computational and Experimental Science. *Virus*, 61, 49-57. http://dx.doi.org/10.2222/jsv.61.49

[5] Schills, S. (2002) The Use of Clay in Fight against Effect of Ammonia. http://www.mistalus.net

[6] World Health Organization (2007) Laboratory Guidelines for Enumerating CD4 T Lymphocytes in the Context of HIV/AIDS. World Health Organization Regional Office for South-East Asia, New Delhi.

[7] Galindo, L.A. and Cereso, P. (2006) Compositional Technical and Safety Specification of Clay to Be Used as Pharmaceutical and Cosmetic Products. *Journal of Renal Nutrition*, 2, 38-40.

[8] Ezeibe, M.C.O. (2014) The Medicinal Synthetic Aluminum-Magnesium Silicate (Nanoparticles)—Antiviral Agent and Adjuvant to Chemotherapeutics. Federal Republic of Nigeria Patents and Designs Ref No.: NG/P/2012/639.

[9] Murray, K.R. (2000) Harpers Biochemistry. McGraw Hill, New York.

[10] Ezeibe, M.C.O., Ngene, A.A., Kalu, I.K., Ezeh, I.O., Mbuko, I.J., Ekwuruwe, J.O., Anene, I., Amechi, B., Olowoniyi, P. and Ifekwe, I.F. (2014) Assessment of Antiretroviral Effects of a Synthetic Aluminum-Magnesium Silicate. *BJMMR*, 4, 1672-1679.

[11] Ezeibe, M.C.O., Mbuko, I.J., Okoroafor, O.N., Okonkwo, A.C., Animoke, P.C., Orajaka, L.J.E. and Ngene, A.A. (2009) In *Vivo* and in *Vivo* Effects of Aluminum-Magnesium Silicate on Infectious bursal Disease Virus in Chikens. *Animal Science Reporter*, 3, 132-137.

[12] Ezeibe, M.C.O., Nwaogu, I.C., Nwaigwe, A.N., Okoroafor, O.N., Eze, J.I. and Ngene, A.A. (2010) Aluminum-Magnesium Silicate Inhibits *Canine parovirus* and Cures Infected Dogs. *Health*, 2, 1215-1217. http://dx.doi.org/10.4236/health.2010.210179

[13] Ezeibe, M.C.O., Ijabi, O., Uzopuo, C., Okoroafor, O.N., Eze, J.I. Mbuko, I.J., Sanda, M.E., and Recovery, P.C. and Ngene, A. A. (2011) Effects of Aluminum-Magnesium Silicate on Newcastle Disease Virus and on Recovery of Infected chicks. *International Journal of Biological and Chemical Sciences*, 5, 825-829. http://dx.doi.org/10.4314/ijbcs.v5i2.72160

[14] Ezeibe M.C.O. (2006) Admacine®. Federal Republic of Nigeria Patents and Designs Act. Cap 344 LFN 1990, NO. RP 16446.

[15] Mark-Cichocki, R.N. (2014) HAART-Highly Active Anti-Retroviral Therapy. aids.about.com

[16] Ezeibe, M.C.O., Okafor, U.C., Okoroafor, O.N., Eze, J.I., Ngene, A.A., Animoke, P.C. and Mbuko, I.J. (2011) Effect of Aluminum-Magnesium Silicate on Anticcocidial Activity of Sulphadimidine. *Tropical Veterinarian*, 29, 41-44.

[17] Ezeibe, M.C.O., Elendu-Eleke, N.P., Okoroafor, O.N. and Ngene, A.A. (2012) Adjuvant Effect of a Synthetic Aluminium-Magnesium Silicate on Chloroquine Phosphate, against *Plasmodium berghei*. *Health*, 4, 448-451. http://dx.doi.org/10.4236/health.2012.48071

[18] Ezeibe, M.C.O., Anosa, G.N., Okorie, O.K., Elendu-Eleke, N.P., Okoroafor, O.N, Ngene, A.A. and Chikelu, O.N. (2012) Aluminum-Magnesium Silicate Enhances Antibacterial Activity of Ampicilline Trihydrate, against *S. gallinarum*. *Nature Proceedings*. http://hdl.handle.net/10101/npre.2012.6814.1

[19] Ezeibe, M.C.O, Dire, C.D., Anosa, G.N., Chikelu, O.N., Okoroafor, O.N., Okorie, O.K., Ngene, A.A., Idika, I.K., Ogumniran, T.M. and Ezeala, I.E. (2012) Efficacy of Paparazine Citrate, Stabilized with Aluminum-Magnesium Silicate, against *Helignosomoides bakeri*. *Health*, 4, 890-892. http://dx.doi.org/10.4236/health.2012.410135

[20] Ezeibe, M.C.O., Chima, U.M., Ngene, A.A., Okoroafor, O.N., Kalu, I.I. and Esen, M.E. (2012) Effective Treatment of Resistant *Escherichia coli* Infection, with Sulphadimidine Stabilized in a Synthetic Aluminum-Magnesium Silicate, against *Helignosomoides bakeri*. *Health*, 4, 1295-1298. http://dx.doi.org/10.4236/health.2012.412190

[21] Ezeibe, M.C.O., Ezeobele, O.K, Esen, M.E., Ngene, A.A., Mbuko, I.J. Chukwudi, I.C., Omoja, V.U. and Ezeh, I.O. (2013) Synergy in Antibacterial Activities of Ampicillin Trihydrate, Stabilized with a Synthetic Aluminum-Magnesium Silicate and Immune-Stimulants, on Resistant *Escherichia coli* Infection. *Health*, 5, 1548-1552. http://dx.doi.org/10.4236/health.2013.510210

[22] Ezeibe, M.C.O and Ogbonna, I.J. (2015) Enhancing Efficacy of Antimicrobials with the Medicinal Synthetic Aluminum-Magnesium Silicate, for Prevention and Treatment of Resistant Infections. *BJMMR*, 9, 1-8.
Ezeibe, M.C.O. and Ogbonna, I.J. (2015) Synergy between Effects of the Medicinal Synthetic Aluminum-Magnesium Silicate and B-Vitamins, on Anti-Plasmodial Activities of Chloroquine. BJMMR. (In Print)